Synergism between paraoxonase Arg 192 and the angiotensin converting enzyme D allele is associated with severity of coronary artery disease

Molecular Biology Reports

Volumn 39, Issue 3, 2012, Pages 2723-2731

  Vaisi Raygani, Asad ^a,b   Rahimi, Zohreh ^a,c   Tavilani, Haidar ^d   Vaisi Raygani, Hadiss ^e   Kiani, A ^c   Aminian, M ^f   Shakiba, E ^a   Shakiba, Y ^a   Pourmotabbed, Tayebeh ^g  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHAHID BAHONAR UNIVERSITY OF KERMAN   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Coronary artery disease; Diabetes mellitus; Genetic polymorphism; Lipid profile; Paraoxonase; Vessel stenosis

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME D; ARGININE; ARYLDIALKYLPHOSPHATASE; DIPEPTIDYL CARBOXYPEPTIDASE; UNCLASSIFIED DRUG;

ACE D GENE; ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GENE; GENE ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE INTERACTION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PON1 ARG 192 GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT;

ALLELES; ARGININE; ARYLDIALKYLPHOSPHATASE; CORONARY ARTERY DISEASE; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDEL MUTATION; IRAN; LINEAR MODELS; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDYL-DIPEPTIDASE A; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS;

EID: 84863837572     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1027-4     Document Type: Article

References (54)

1. Kharrazi H, Vaisi-Raygani A, Sabokroh AR, Pourmotabbed T (2006) Association between apolipoprotein E polymorphism and coronary artery disease in the Kermanshah population in Iran. Clin Biochem 39:613-616
2. Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T (2007) The presence of apolipoprotein e4 and e2 alleles augments the risk of coronary artery disease in type 2 diabetic patients. Clin Biochem 40:1150-1156
3. Rahimi Z, Vaisi-Raygani A, Pourmotaabed T (2011) Association between apolipoprotein e4 allele, factor V leiden, and plasma lipid and lipoprotein levels with sickle cell disease in Southern Iran. Mol Biol Reports 38(2):703-710
4. Vaisi Raygani A, Rahimi Z, Entezami H, Kharrazi H, Bahrhemand F, Tavilani H, Rezaei M, Kiani A, Nomanpour B, Tavilani H, Pourmotabbed T (2008) Butyrylcholinesterase K variants increase the risk of coronary artery disease in the population of western Iran. Scandin J Clin Lab Invest 68(2):123-129
5. Vaisi Raygani A, Rahimi Z, Tavilani H, Pourmotabbed T (2010) Butyrylcholinesterase K variant and the APOE-e4 allele work in synergy to increase the risk of coronary artery disease especially in diabetic patients. Mol Bio Rep 37(4):2083-2091
6. Vaisi Raygani A, Tavilani H, Zahrai M, Rahimi Z, Sheikh N, Aminian M, Pourmotabbed T (2009) Serum butyrylcholinesterase activity and phenotype associations with lipid profile in stroke patients. Clin Biochem 42:210-214
7. Hatmi ZN, Tahvildari S, Gafarzadeh Motlag A, Sabouri Kashani A (2007) Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovascu Disord 7(32):1-5
8. Imazio M, Bobbio M, Bergerone S, Barlera S, Maggioni AP (1998) Clinical and epidemiological characteristics of juvenile myocardial infarction in Italy: the GISSI experience. J Ital Cardiol 28(5):505-512
9. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhi-ainen M (1996) The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 98:883-885
10. Gupta N, Gill K, Singh S (2009) Paraoxonases: structure, gene polymorphism &role in coronary artery disease. Indian J Med Res 130:361-368
11. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshina H et al (1997) A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in Japanese. Arterioscler Thromb Vasc Biol 17:3565-3569
12. Pfohl M, Koch M, Enderle MD, Kuhn R, Fullhase J, Karsch KR, Haring HU (1999) Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 48:623-627
13. Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S, Hamda K, Farhat M, Miled A, Hammami M (2009) Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem 42:771-776
14. Davies HG (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336
15. La Du BN (1996) Structural, functional diversity of paraoxonases. Nat Med 2:1186-1187
16. Aviram M (1999) Does paraoxonase play a role in susceptibility to cardiovascular disease? Mole Medici Today 5:66-78
17. Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K (2001) Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraoxonase 1 gene (Q192R) polymorphism? Euro J Endocrin 144:639-644
18. Ruiz J, Blanche H, James RW, Garin MC, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P (1995) Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872
19. Sekuri C, Cam FS, Ercan E, Tengiz I, Sagcan A, Eser E et al (2005) Renin-angiotensin system gene polymorphisms and premature coronary heart disease. JRAAS 6:38-42
20. Ermis C, Tsai MY, Hanson NQ, Akar N, Aras O (2002) Angiotensin I converting enzyme, angiotensin II type I receptor and angiotensinogen polymorphisms and early myocardial infarction in Turkish population. Thromb Haemost 88:693-694
21. Alvarez R, Reguero JR, Batalla A (1998) Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res 40:375-379
22. Dzimiri N, Basco C, Moorji A, Meyer BF (2000) Angiotensinconverting enzyme polymorphism and the risk of coronary heart disease in the Saudi male population. Arch Pathol Lab Med 124(4):531-534
23. Hoshida S, Kato J, Nishino M, Egami Y, Takeda T, Kawabata M et al (2001) Increased angiotensin-converting enzyme activity in coronary artery specimens from patients with acute coronary syndrome. Circulation 103(5):630-633
24. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, Nomani H, Saidi M, Bahrehmand F, Vaisi-Raygani A, Tavilani H, Pourmotabbed T (2010) The angiotensin converting enzyme D allele is an independent risk factor for early onset coronary artery disease. Clin Biochem 43:1189-1194
25. WHO Study Group Report of a WHO consultation: Part 1. Diagnosis and classification of diabetes mellitus. World Health Organization 1999; Geneva
26. Raygani AV, Rahimi Z, Kharazi H, Tavilani H, Pourmotabbed T (2006) Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci Lett 6 408(1):68-72
27. Tiret L, Rigat B, Visvikis S, Breda C, Corovol P, Cambien F, Soubrier F (1992) Evidance, from combined segregation and linkage analaysis, that a variant of the angiotensin converting enzyme(ACE) gene controls plasma ACE level. Am J Hum Genet 51:197-205
28. Mohamed RH, Mohamed RH, Karam RA, Abd El-Aziz TA (2010) The relationship between paraoxonase1-192 polymorphism and activity with coronary artery disease. Clin Biochem 43:553-558
29. Aydin M, Gokkusu C, Ozkok E, Tulubas F, Unlucerci Y, Pamukcu B, Ozbek Z, Umman B (2009) Association of genetic variants in methylenetetrahydrofolate reductase and paraoxonase-1 genes with homocysteine, folate and vitamin B12 in coronary artery disease. Mol Cell Biochem 325:199-208
30. Odawara M, Tachi Y, Yamashitya K (1997) Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:2257-2260
31. Serrato M, Marian AJ (1995) A variant of human paraoxonase/ arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96:3005-3008
32. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 28:363(9410):686-695
33. Debbie T, Lawlor A, Day INM, Gaunt TR, Hinks LJ, Briggs PJ, Kiessling M, Timpson N, Smith GD, Ebrahim S (2004) The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's heart and health cohort study and a meta-analysis. BMC Genet 5(17):1-13
34. Task?ran P, Cam SF, Sekuri C, Tuzun N, Alioglu E, Alt?ntas N, Berdeli A (2009) The relationship between paraoxanase gene Leu-Met (55) and Gln-Arg (192) polymorphisms and coronary artery disease. Arch Turk Soc Cardiol 37(7):473-478
35. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K (1996) Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 57:69-73
36. Sanghera DK, Saha N, Aston CE, Kamboh MI (1997) Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17:1067-1073
37. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques Vidal P, Bard JM, Cambien F (1996) The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Athersclerosis 126:299-303
38. Heijmans BT, Westendorp RG, Lagaay AM, Knook DL, Kluft C, Slagboom PE (2000) Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 149:91-97
39. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1998) Effect of the human serum PON1 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57-60
40. Aviram M, Fuhrman B (1998) LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants. Mol Cell Biochem 188:149-159
41. Mackness MI (1998) Paraoxonase and coronary heart disease. Curr Opin Lipidol 9:319-324
42. Heinecke JW, Lusis AJ (1998) Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 62:20-24
43. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for PON1. J Clin Invest 101:1581-1590
44. Ajmal M, Ahmed W, Sadeque A, Ali SH, Bokhari SH, Ahmed N, Qamar R (2010) Identification of a recurrent insertion mutation in the LDLR gene in a Pakistani family with autosomal dominant hypercholesterolemia. Mol Biol Rep 37(8):3869-3875
45. AshokKumar M, Subhashini NG, SaiBabu R, Ramesh A, Cherian KM, Emmanuel C (2010) Genetic variants on apolipoprotein gene cluster influence triglycerides with a risk of coronary artery disease among Indians. Mol Biol Rep 37(1):521-527
46. Nikzamir A, Nakhjavani M, Golmohamadi T, Dibai L (2008) Association of angiotensin-converting enzyme gene insertion/ deletion polymorphism with metabolic syndrome in Iranians with type 2 diabetes mellitus. Arch Iranian Med 11(1):3-9
47. Bayram B, Say?n E, Gunes HV, Deg?irmenci I, Turkog?lu Z, Doganer F, Cosan DT (2011) DD genotype of ace gene I/D polymorphism is associated in a Turkish study population with osteoarthritis. Mol Biol 38(3):1713-1716
48. Rahimi Z, Felehgari V, Rahimi M, Mozafari H, Yari K, Vaisi-Raygani A, Rezaei M, Malek-Khosravi S, Khazaie H (2011) The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria. Mol Biol Rep 38(3):2117-2123
49. Sabbagh AS, Otrock ZK, Mahfoud ZR, Zaatari GS, Mahfouz RA (2007) Angiotensin-converting enzyme gene polymorphism and allele frequencies in the Lebanese population: prevalence and review of the literature. Mol Biol Rep 34(1):47-52
50. Tiret L, Bonnardeaux A, Poirier (1994) Synergistic effects of angiotensin-converting enzyme and angiotensin II type 1 receptor DD genotype of the gene polymorphisms on risk of myocardial infarction. Lancet 344:910-913
51. Cambien F, Poirier O, Lecerf L et al (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359:641-644
52. Shafiee SM, Firoozrai M, Salimi S, Zand H, Hesabi B, Mohebbi A (2010) Angiotensin converting enzyme DD genotype not associated with increased risk of coronary artery disease in the Iranian population. Pathophysiology 17(3):163-167
53. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delepine M, Lathrop M, Peto R, Collins R (2000) Largescale test of hypothesized associations between the angiotensinconverting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 control subjects: international studies of infarct survival (ISIS) collaborators. Lancet 355:434-442
54. Turgut S, Ak?n F, Akc?lar R, Ayada C, Turgut G (2011) Angiotensin converting enzyme I/D, angiotensinogen M235T and AT1-R A/C1166 gene polymorphisms in patients with acromegaly. Mol Biol Rep 38(1):569-576